Skip to main content

Table 1 RTOG studies included in analysis

From: The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group

Study Phase Description N = 153
7401 III WBRT+(BCNU vs. MeCCNU+DTIC) 38 (25%)
7918 III WBRT+(BCNU vs. Misonidazole radiosensitizer & BCNU) 9 (6%)
8302 III Hyperfractionated and Accelerated RT + BCNU 30 (20%)
8409 I/II WBRT + AZQ (NSC-182986) 1 (1%)
9006 III BCNU + (Hyperfractionated RT vs. RT) 32 (21%)
9305 III +/-SRS followed by RT+BCNU 3 (2%)
9602 II RT + Taxol 13 (8%)
9806 II RT + Thalidomide 27 (18%)